Por: Los Angeles Times Science October 20, 2022
A federal advisory panel voted Wednesday to recommend that the only approved drug to prevent premature birth be removed from pharmacy shelves because studies have shown it does not work. The 14-to-1 vote came more than a decade after the Food and Drug Administration approved the drug, called Makena, on limited evidence, citing the great need for such a treatment. The Times detailed in a February 2022 investigation how the drug’s maker —... + full article
WPLG Local 10 USA Health October 19, 2022
WASHINGTON – Federal health advisers have concluded that a drug intended to prevent premature births hasn't been shown to work, clearing the way for U.S. regulators to follow through on a long-delayed effort to get it off the market.The Food and Drug Administration’s... + más
FDA panel backs removal of unproven pregnancy drug | 10 WBNS
FDA panel backs removal of unproven pregnancy drug | ABC News
CNBC USA Health October 19, 2022
An advisory panel to the Food and Drug Administration voted Wednesday to take a drug intended to prevent premature births off the market, saying that it remains doubtful that the drug works.The recommendation, in a 14-1 vote, from the agency's Obstetrics, Reproductive and... + más
FDA panel backs removal of unproven pregnancy drug | WPLG Local 10
ALS drug wins FDA approval despite questionable data | ABC News
10 WBNS USA Health October 19, 2022
WASHINGTON — Federal health advisers ruled Wednesday that a drug intended to prevent premature births doesn’t work, clearing the way for U.S. regulators to follow through on a long-delayed effort to get it off the market. The Food and Drug Administration’s advisory panel... + más
ABC News USA Health October 19, 2022
WASHINGTON -- Federal advisers have concluded that a drug intended to prevent premature births hasn't been shown to work, clearing the way for U.S. regulators to follow through on a long-delayed effort to get it off the market.The Food and Drug Administration’s advisory... + más
Time USA Health October 19, 2022
WASHINGTON — Federal health advisers have concluded that a drug intended to prevent premature births hasn’t been shown to work, clearing the way for U.S. regulators to follow through on a long-delayed effort to get it off the market. The Food and Drug Administration’s... + más
Portland Press Herald USA Health October 19, 2022
WASHINGTON — Federal health advisers have concluded that a drug intended to prevent premature births hasn’t been shown to work, clearing the way for U.S. regulators to follow through on a long-delayed effort to get it off the market. A panel of federal advisers says Makena,... + más
NBC 6 South Florida USA World October 19, 2022
Makena Federal health advisers have concluded that a drug intended to prevent premature births hasn't been shown to work, clearing the way for U.S. regulators to follow through on a long-delayed effort to get it off the market. The ’s advisory panel voted 14-1 Wednesday... + más
FDA panel recommends revoking the approval of controversial drug intended to prevent premature birth | CNBC
FDA panel backs removal of unproven pregnancy drug | Portland Press Herald
About iurex | Privacy Policy | Disclaimer |